Trulieve Makes History with NYSE Listing, Announces $50 Million Share Buyback
09.06.2026 - 19:24:59 | boerse-global.de
Trulieve Cannabis, the Florida-based medical marijuana giant, is set to become the first U.S. cannabis producer to land a listing on the New York Stock Exchange. The milestone arrived alongside an unexpected confidence vote from management: a share buyback program worth up to $50 million.
The board authorized repurchasing up to five percent of outstanding voting shares over the next twelve months, with all bought-back stock set to be canceled. The move underscores the company’s belief that its equity is undervalued even after a blistering rally.
Regulatory Shift Opened the Door
The NYSE listing was made possible by a fundamental change in federal drug policy. In April 2026, the U.S. government reclassified medical marijuana as a Schedule III substance under the Controlled Substances Act, a shift enabled by an executive order from President Trump.
That reclassification removed a major regulatory hurdle that had long kept cannabis companies off major exchanges. For Trulieve, it triggered a sweeping corporate overhaul designed to meet NYSE listing requirements.
Should investors sell immediately? Or is it worth buying Trulieve?
The company spun off its recreational cannabis business into a separate entity called Harvest Enterprises. The remaining core now consists exclusively of state-licensed medical marijuana operations spanning Florida, Georgia, Pennsylvania, and West Virginia. The medical division operates 206 dispensaries and commands an estimated 40 percent of the Florida market, with total production capacity reaching 3.5 million square feet.
An additional financial tailwind came from the rescheduling: Trulieve’s medical segment is no longer subject to the onerous IRS Section 280E tax provision, which had historically prevented cannabis companies from deducting ordinary business expenses.
Rally Stalls, Then Resumes
The stock has been on a tear in the months leading up to the listing. After briefly touching a new 52-week high of €11.48, shares pulled back sharply, shedding roughly seven percent to hit €10.10. But the dip was short-lived — the stock has since recovered to trade at €11.14, just 0.18 percent shy of its current 52-week high of €11.16.
Over the past twelve months, Trulieve has surged 225 percent, with a 39.4 percent gain in the last week alone. The relative strength index now sits at 77.0, signaling that the stock is in overbought territory. Still, multiple analysts maintain a “Strong Buy” rating, citing the enhanced visibility the NYSE listing brings to the company.
Trulieve at a turning point? This analysis reveals what investors need to know now.
What Comes Next
Investors now have their eyes on the next regulatory catalyst. On June 29, 2026, the Drug Enforcement Administration has scheduled a hearing to discuss the potential expansion of Schedule III classification to recreational cannabis. Separately, local residents in Jefferson County, Florida, have petitioned for a review of Trulieve’s facility in the area, adding a note of operational risk.
The NYSE debut, scheduled for Wednesday under the ticker “TRLV,” marks a watershed moment not only for Trulieve but for the broader U.S. cannabis sector. The accompanying buyback program — valued at up to $50 million — signals that management sees further upside even as the stock trades near record levels. Whether the listing will sustain the momentum depends largely on how the regulatory landscape continues to evolve.
Ad
Trulieve Stock: New Analysis - 9 June
Fresh Trulieve information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Trulieve Aktien ein!
FĂĽr. Immer. Kostenlos.
